LAUSR

As the prevalence of Parkinson disease (PD) continues to rise, the need for specific and reliable biomarkers is paramount. A biomarker is an objective measure of disease and may help confirm diagnosis, track disease progression, or identify targets for therapeutic development.1 Many clinicians and scientists are devoting time and effort to the discovery and validation of such tools, which would improve clinical management of patients with PD. Indeed, the development of early diagnostic biomarkers could help identify at-risk individuals and allow precocious interventions at the onset of disease and more precise monitoring of therapies that may slow disease progression.2